Comparison of metabolic effects of surgical-induced massive weight loss in patients with long-term remission versus non-remission of type 2 diabetes

Obesity Surgery

Volumn 22, Issue 6, 2012, Pages 910-917

  Hirsch, Fernanda Filgueira ^a   Pareja, Jose Carlos ^a   Geloneze, Sylka Rodovalho ^a   Chaim, Elinton ^a   Cazzo, Everton ^a   Geloneze, Bruno ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

adiponectin; Bariatric surgery; Diabetes; Gastroplasty; incretins; insulin resistance; Monocyte chemoattractant protein (MCP 1)

Indexed keywords

ADIPONECTIN; C PEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; ORAL ANTIDIABETIC AGENT; URIC ACID;

ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY FAT DISTRIBUTION; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEUKOCYTE; MALE; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; ROUX Y ANASTOMOSIS; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADIPONECTIN; ADOLESCENT; ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; BODY MASS INDEX; BRAZIL; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRIC BYPASS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; LEUKOCYTES; MALE; MIDDLE AGED; OBESITY, MORBID; REMISSION INDUCTION; RETROSPECTIVE STUDIES; URIC ACID; WEIGHT LOSS; YOUNG ADULT;

EID: 84862631254     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-012-0589-0     Document Type: Article

References (25)

1. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106:473-81.
2. Sjöström L, Narbro K, Sjöström CD, et al. Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741-52.
3. Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32:2133-5.
4. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
5. Mari A, Pacini G, Murphy E, et al. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care. 2001;23:539-48.
6. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing. Comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462-70.
7. Seltzer HS, Allen EW, Herron Jr AL, et al. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest. 1967;46:323-35.
8. Mari A, Ahrén B, Pacini G. Assessment of insulin secretion in relation to insulin resistance. Curr Opin Clin Nutr Metab Care. 2005;8:529-33.
9. Retnakaran R, Qi Y, Goran MI, et al. Evaluation of proposed oral disposition index measures in relation to the actual disposition index. Diabet Med. 2009;26:1198-203.
10. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and metaanalysis. Am J Med. 2009;122:248-56.
11. Laferrère B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007;30:1709-16.
12. Rosa G, Mingrone G, Euthine V, et al. Molecular mechanisms of diabetes reversibility after bariatric surgery. Int J Obes. 2007;31:1429-36.
13. Camastra S, Manco M, Mari A, et al. β-cell function in severely obese type 2 diabetic patients. Diabetes Care. 2007;30:1002-4.
14. Andreelli F, Amouyal C, Magnan C, et al. What can bariatric surgery teach us about the pathophysiology of type 2 diabetes? Diabetes Metab. 2009;35:499-507.
15. Hall TC, Pellen MG, Sedman PC, et al. Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity. Obes Surg. 2010;20:1245-50.
16. Ballantyne GH, Gumbs A, Modlin IM. Changes in insulin resistance following bariatric surgery and adipoinsular axis: role of the adipocytokines, leptin, adiponectin and resistin. Obes Surg. 2005;15:692-9.
17. Bays HE, Laferrère B, Dixon J, et al. Adiposopathy and bariatric surgery: is 'sick fat' a surgical disease? Int J Clin Pract. 2009;63:1285-300.
18. Geloneze B, Tambascia MA, Pareja JC, et al. Serum leptin levels after bariatric surgery across a range of glucose tolerance from normal to diabetes. Obes Surg. 2001;11:693-8.
19. Faraj M, Havel PJ, Phélis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2003;88:1594-602.
20. Geloneze B, Pereira JA, Pareja JC, et al. Overcoming metabolic syndrome in severe obesity: adiponectin as a marker of insulin sensitivity and HDL-cholesterol improvements after gastric bypass. Arq Bras Endocrinol Metabol. 2009;53:293-300.
21. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest. 2007;117:24-32.
22. le RouxCW, Aylwin SJB, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243:108-14.
23. Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and β-cell function in type 2 diabetes. Diabetes Care. 2009;32:514-20.
24. Kashyap SR, Daud S, Kelly KR, et al. Acute effects of gastric bypass versus gastric restrictive surgery on β-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes. 2010;34:462-71.
25. Muscelli E, Mingrone G, Camastra S, et al. Differential effect of weight loss on insulin resistance in surgically treated obese patients. Am J Med. 2005;118:51-7.